We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisors Wary of Sanofi’s Lemtrada as First-Line MS Drug
FDA Advisors Wary of Sanofi’s Lemtrada as First-Line MS Drug
A panel of FDA advisors Nov. 14 overwhelmingly voted against approval of Sanofi’s Lemtrada for an expanded indication to treat relapsing multiple sclerosis (MS).